is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

Carlos Santamaría (1, 2, 3) , María C. Chillón (1) , Ramón García-Sanz (1, 2) , Cristina Pérez (4) , María D. Caballero (1) , María V. Mateos (1) , Fernando Ramos (5) , Alfonso García Coca (6) , José M. Alonso (7) , Pilar Giraldo (8) , Teresa Bernal (9) , José A. Queizán (10) , Juan N. Rodríguez (11) , Noemí Puig (1) , Ana Balanzategui (1) , María E. Sarasquete (1) , Miguel Alcoceba (1) , Joaquín Díaz-Mediavilla (4) , Jesús San Miguel (1, 2) , Marcos González (1, 2)

1 Hospital Universitario
2 Centro de Investigación del Cáncer-IBMCC (USAL-CSIC)
3 Department of Hematology
4 Hospital Clínico San Carlos
5 Complejo Hospitalario de León and Ibiomed
6 Hospital Clínico de Valladolid
7 Hospital Río Carrión de Palencia
8 Hospital Universitario Miguel Servet
9 Hospital Central de Asturias
10 Hospital General de Segovia
11 Hospital Juan Ramón Jiménez

We have analyzed brain and acute leukemia, cytoplasmic () gene expression and other genetic markers (, , , , , , and mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low expressers showed a higher refractoriness to induction treatment (31% vs 10%;  = .005), lower complete remission rate after salvage therapy (82% vs 97%;  = .010), and lower 3-year overall (23% vs 58%,  < .001) and relapse-free survival (26% vs 52%,  = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, is a relevant prognostic marker in intermediate-risk AML.

Mots clés: Acute myeloid leukemia; Prognostic factor; Intermediate-risk cytogenetics

Carlos Santamaría, María C. Chillón, Ramón García-Sanz, Cristina Pérez, María D. Caballero, et al.. is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Annals of Hematology, 2009, 89 (5), pp.453-458. ⟨10.1007/s00277-009-0864-x⟩. ⟨hal-00535106⟩